Claims for Patent: 9,713,625

Summary for Patent: 9,713,625

Title:	MicroRNAs useful for treating ovarian cancer
Abstract:	Described herein are methods for diagnosing ovarian cancer. In particular, certain microRNAs are useful to the response to chemotherapy of ovarian cancer patients.
Inventor(s):	Croce; Carlo M. (Columbus, OH), Vecchione; Andrea (Rome, IT)
Assignee:	The Ohio State University (Columbus, OH)
Application Number:	14/989,432
Patent Claims:	1. A method of increasing sensitivity to chemotherapeutic intervention in a subject with ovarian cancer, comprising: increasing levels of miR-484 expression in ovarian cancer cells of the subject by administering at least one miR-484 gene product to ovarian cancer cells of the subject in an amount sufficient to increase the efficacy of the chemotherapeutic intervention; and, administering the chemotherapeutic intervention to the subject either before, after or simultaneously with the miR-484 gene product, wherein the chemotherapeutic intervention is carboplatin or taxol treatments or a combination thereof. 2. The method of claim 1, wherein the miR-484 gene product is delivered by plasmids or viral vectors. 3. The method of claim 1, wherein the ovarian cancer cells are serous epithelial ovarian carcinoma cells. 4. The method of claim 1, wherein the miR-484 gene product is nucleic acid is selected from the group consisting of a single-stranded RNA, a single-stranded DNA, a single-stranded RNA-DNA chimera and a single-stranded RNA. 5. The method of claim 1, wherein miR-484 gene product comprises a nucleic acid containing one or more modifications to the nucleic acid backbone, a sugar moiety, a base moiety or a combination thereof. 6. The method of claim 5, wherein the miR-484 gene product is at least 95% complementary to a contiguous nucleotide sequence having SEQ ID NO:11. 7. The method of claim 5, wherein the nucleic acid is 100% complementary to a contiguous nucleotide sequence in a miR-484 gene product having SEQ ID NO:11. 8. The method of claim 1, wherein the miR-484 gene product is delivered to the ovarian cancer cells in a pharmaceutical composition comprising a pharmaceutically-acceptable carrier. 9. The method of claim 8, further comprising administering one or more additional pharmaceutical agents. 10. The method of claim 1, wherein the one or more additional pharmaceutical agents comprises one or more of: a platinum-based drug, carboplatin, cisplatin, a taxane, paclitaxel, docetaxel, gemcitabine, doxorubicin, etoposide, vinorelbine, xabepilone, an epithelone drug, bevacizumab, and phenoxodiol. 11. A method of increasing sensitivity to chemotherapeutic intervention in a subject with ovarian cancer, comprising increasing levels of miR-484 expression in ovarian cancer cells of the subject by administering at least one miR-484 gene product to ovarian cancer cells of the subject in an amount sufficient to increase the efficacy of the chemotherapeutic intervention; and, administering the chemotherapeutic intervention to the subject either before, after or simultaneously with the miR-484 gene product, wherein the chemotherapeutic intervention is carboplatin or taxol treatments or a combination thereof; further comprising increasing levels of miR-296 expression in ovarian cancer cells of the subject by delivering at least one miR-296 gene product to the ovarian cancer cells of the subject. 12. The method of claim 11, wherein the miR-296 gene product is delivered by plasmids or viral vectors. 13. The method of claim 11, wherein the miR-296 gene product is nucleic acid is selected from the group consisting of a single-stranded RNA, a single-stranded DNA, a single-stranded RNA-DNA chimera and a single-stranded RNA. 14. The method of claim 11, wherein miR-296 gene product comprises a nucleic acid containing one or more modifications to the nucleic acid backbone, a sugar moiety, a base moiety or a combination thereof. 15. The method of claim 14, wherein the miR-296 gene product is at least 95% complementary to a contiguous nucleotide sequence having SEQ ID NO:9. 16. The method of claim 14, wherein the nucleic acid is 100% complementary to a contiguous nucleotide sequence in a miR-296 gene product having SEQ ID NO:9.

Details for Patent 9,713,625

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-10-14